EG-Mirotin is a RGD motif containing recombinant polypeptide from human derived protein. It has 6.1-kDa of molecular weights (composed of over 58 amino acids) and easily produced from the yeast. EGT022 promotes healthy and stable blood vessel formation.
EG-Mirotin is a potent inducer of several growth factors of the platelet. When administered in low doses via IM, it induces several growth factors and consequently enhances normal blood vessel formation and stabilization. Animal studies have demonstrated its stabilization and maturation capabilities in newly formed vasculature in the retina.
EG-Mirotin is currently being tested for pre-clinical toxicity in European Union.
EG-Mirotin induces stabilization and maturation of abnormal retinal vasculature in oxygen induced retinopathy (OIR) model.
Abnormally swollen ganglion cell layer (GCL) and excess of blood vessel profiles (BVP) caused by OIR is reduced by administration of EG-Mirotin.
It is elucidated once the retina is irreversibly ischemia and/or new vessels have formed, VEGF may lead to retinal necrosis due to chronic ischemia. Repetitively, it would be continued in OIR. However, an alternative approach by EG-Mirotin may disequilibrate the balance and induce neovascular maturation.
Co-development and Licensing Out
Yong U KIM
Business Development Manager
Health Technology Transfer Center
KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.View profile
Clients in focus...